Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.(1) Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments(2) and could serve as an option for patients with MASH. Few studies have examined the efficacy of GLP-1 receptor agonists in MASH. In a phase 2 trial, treatment with semaglutide - a GLP-1 receptor agonist - led to resolution of steatohepatitis in 40 to 59% of patients but fell short of showing a significant reduction in . . .